NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its Twin® platform, announced today that an abstract related to IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The poster will share data from one of the Phase 2 basket trials o ...